• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual Meeting
November 07, 2024
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Tickers BOLT
Bolt Biotherapeutics Announces Changes to its Board of Directors
September 04, 2024
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Tickers BOLT
Bolt Biotherapeutics to Participate in Upcoming September Conferences
August 28, 2024
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Tickers BOLT
Bolt Biotherapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
August 13, 2024
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Tickers BOLT
Bolt Biotherapeutics Reports First Quarter 2024 Results, Announces Strategic Pipeline Prioritization and Changes to Leadership Team
May 14, 2024
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Tickers BOLT
Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
March 21, 2024
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Tickers BOLT
Bolt Biotherapeutics to Present at the TD Cowen 44th Annual Healthcare Conference
February 27, 2024
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Tickers BOLT
Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu®
December 05, 2023
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Tickers BOLT
Bolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
November 09, 2023
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Tickers BOLT
Bolt Biotherapeutics to Present at Stifel 2023 Healthcare Conference
November 07, 2023
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Tickers BOLT
Bolt Biotherapeutics Presents Updated Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at ESMO 2023 Congress
October 23, 2023
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Tickers BOLT
Bolt Biotherapeutics to Present Data at the Society for Immunotherapy of Cancer’s 2023 Annual Meeting
October 18, 2023
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Tickers BOLT
Bolt Biotherapeutics Announces First Patient Dosed in Phase 1/2 Study of BDC-3042 in Patients with Advanced Cancers
October 17, 2023
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Tickers BOLT
Bolt Biotherapeutics to Present New Clinical Data from Completed Phase 1/2 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Solid Tumors at the ESMO Congress 2023
October 16, 2023
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Tickers BOLT
Bolt Biotherapeutics Receives Orphan Drug Designation for BDC-1001 for Treatment of Gastric Cancers
September 28, 2023
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Tickers BOLT
Bolt Biotherapeutics Announces Issuance of U.S. Patent Covering Dectin-2-Targeting Agonist Antibodies, Including BDC-3042
September 12, 2023
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Tickers BOLT
Bolt Biotherapeutics to Participate in September Investor Conferences
September 05, 2023
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Tickers BOLT
Bolt Biotherapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
August 07, 2023
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Tickers BOLT
Bolt Biotherapeutics Initiates Phase 2 Clinical Studies of BDC-1001 in Patients With HER2-Positive Cancer
August 03, 2023
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Tickers BOLT
Bolt Biotherapeutics to Present at BTIG Virtual Biotechnology Conference 2023
July 31, 2023
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Tickers BOLT
Bolt Biotherapeutics Highlights Comprehensive Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at 2023 ASCO Annual Meeting
May 25, 2023
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Tickers BOLT
Bolt Biotherapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
May 11, 2023
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Tickers BOLT
Bolt Biotherapeutics to Present Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Tumors at 2023 ASCO Annual Meeting
April 26, 2023
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Tickers BOLT
Bolt Biotherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
March 29, 2023
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Tickers BOLT
Bolt Biotherapeutics Announces Positive Topline Data from BDC-1001 Phase 1 Dose-Escalation Trial in HER2-Expressing Tumors, Supporting Advancement to Phase 2 Clinical Studies
March 29, 2023
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Tickers BOLT
Bolt Biotherapeutics to Present Preclinical Data for BDC-3042, a Dectin-2-Targeting Agonistic Antibody, at 2023 AACR Annual Meeting
March 14, 2023
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Tickers BOLT
Bolt Biotherapeutics to Present at Cowen 43rd Annual Healthcare Conference
February 28, 2023
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Tickers BOLT
Bolt Biotherapeutics to Present at February Investor Conferences
February 01, 2023
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Tickers BOLT
Bolt Biotherapeutics Appoints Laura Berner to Board of Directors
December 14, 2022
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Tickers BOLT
Bolt Biotherapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
November 10, 2022
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Tickers BOLT
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap